When was Darzalex first synthesized

Drug Prescription Report 2018 pp 645-691 | Cite as

  • Wolf-Dieter Ludwig
  • Ulrich Schwabe
  • 1Citations
  • 2.1kDownloads


Hormone antagonists for the treatment of breast cancer and prostate cancer, which account for almost 70% of the defined daily dose (DDD), have the highest volume of prescriptions for oncological drugs. In second place are the classic cytostatics with the leading group of antimetabolites, which is mainly based on the frequent prescriptions of 5-fluorouracil. The next groups are monoclonal antibodies and protein kinase inhibitors. The leading groups of monoclonal antibodies are still HER2 antibodies for the treatment of HER2-positive breast cancer, followed by antibodies against VEGF, CD20 and PD-1 receptors, which are indicated for a growing spectrum of oncological indications. The leading representative of the protein kinase inhibitors continues to be imatinib, the successful standard for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. Other protein kinase inhibitors are mainly used to treat chronic lymphocytic leukemia, primary myelofibrosis, non-small cell lung carcinoma, renal cell carcinoma, melanoma, colorectal carcinoma and breast cancer.

This is a preview of subscription content, log in to check access.


Unable to display preview. Download preview PDF.


  1. Adams JL, Smothers J, Srinivasan R, Hoos A (2015): Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14: 603-622 Google Scholar
  2. Al-Lazikani B, Banerji U, Workman P (2012): Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30: 679-692 Google Scholar
  3. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009): Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109-3116 Google Scholar
  4. Apperley JF (2015): Chronic myeloid leukemia. Lancet 385: 1447-1459 Google Scholar
  5. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016): Prostate cancer. Lancet 387: 70-82 Google Scholar
  6. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884Google Scholar
  7. Barbui T, Finazzi MC, Finazzi G (2012): Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 26: 205-211 Google Scholar
  8. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators (2014): Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371: 424-433 Google Scholar
  9. Beyer J, Albers P, Altena R, Aparicio J et al (2013): Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24: 878-888 Google Scholar
  10. Federal Ministry of Health (2014): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V), Ruxolitinib from November 6, 2014, published Monday, December 15, 2014, BAnz AT December 15, 2014 B4Google Scholar
  11. Federal Ministry of Health (2015): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V) Eribulin (new field of application) of January 22, 2015, published on Monday, February 16, 2015 BAnz AT February 16, 2015 B3 Page 1 of 9Google Scholar
  12. Federal Ministry of Health (2016a): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V) Elotuzumab of December 1, published on Wednesday, December 28, 2016 BAnz AT December 28, 2016 B2 Page 1 of 6Google Scholar
  13. Federal Ministry of Health (2016b): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V) Crizotinib (new area of ​​application) from June 16, 2016 published on Tuesday, September 20, 2016 BAnz AT September 20, 2016 B2Google Scholar
  14. Federal Ministry of Health (2016c): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V) Ramucirumab (new area of ​​application) of September 1, 2016, published on Thursday, September 22, 2016 BAnz AT September 22, 2016 B3 Page 1 of 4
  15. Federal Ministry of Health (2016d): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V) Ramucirumab (new area of ​​application) from September 1, 2016, published on Friday, September 16, 2016 BAnz AT September 16, 2016 B1 Page 1 of 6Google Scholar
  16. Federal Ministry of Health (2018a): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V) Carfilzomib (Re-evaluation of an orphan drug according to on drugs with new active ingredients according to From February 15, 2018, Published on Friday, March 9, 2018 BAnz AT 03/09/2018 B2 Page 1 of 10Google Scholar
  17. Federal Ministry of Health (2018b): Announcement of a resolution of the Federal Joint Committee on an amendment to the Drugs Directive (AM-RL): Annex XII - Resolutions on the benefit assessment of drugs with new active ingredients according to Section 35a of Book V of the Social Code (SGB V) Daratumumab (new area of ​​application; reassessment of an orphan drug after exceeding the 50 million euro limit) from February 15, 2018, published on Thursday, March 15, 2018 BAnz AT 03/15/2018 B3Google Scholar
  18. Byrd JC, Brown JR, O ‹Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J , Clow F, James DF, Hillmen P; RESONATE Investigators (2014a): Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371: 213-223 Google Scholar
  19. Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM (2014b): Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician. J Clin Oncol 32: 3039-3047 Google Scholar
  20. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland- Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team (2017): 11 years ’follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389: 1195-1205 Google Scholar
  21. Cervantes F (2014): How I treat myelofibrosis. Blood 124: 2635-2642 Google Scholar
  22. Cheson BD, Leonard JP (2008): Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359: 613-626 Google Scholar
  23. Cheson BD, Rummel MJ (2009): Bendamustine: rebirth of an old drug. J Clin Oncol 27: 1492-1501 Google Scholar
  24. Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X (2015): New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 36: 587-595Google Scholar
  25. Choueiri TK, Motzer RJ (2017): Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 376: 354-366 Google Scholar
  26. Ciardiello F, Tortora G (2008): EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174 Google Scholar
  27. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002): CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242 Google Scholar
  28. Collins FS, Varmus H (2015): A new initiative on precision medicine. N Engl J Med 372: 793-795 Google Scholar
  29. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators (2011): Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 377: 914-923 Google Scholar
  30. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004): A randomized comparison of cetuximab monotherapy and cetuximab plus Irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345 Google Scholar
  31. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC / LATTE investigators (2010): Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135-1141Google Scholar
  32. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators (2010): Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376: 1147-1154 Google Scholar
  33. Deutsche Krebsgesellschaft e.V., Deutsche Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachverbindungen e.V. (Ed.) (2016): Interdisciplinary guideline of quality S3 for early detection, diagnosis and therapy of the different stages of prostate cancer. Long version 4.0 - December 2016, AWMF register number 043 / 022OL. Leading professional society German Society for Urology e. V. (DGU). Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
  34. Deutsche Krebsgesellschaft eV, Deutsche Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachverbindungen eV (Ed.) (2017): Consultation version of the S3 guideline for early detection, diagnosis, therapy and follow-up care for breast cancer, long version 0.4.0 - June 2017, AWMF register number: 032-045OL Leading professional societies German Society for Gynecology and Obstetrics (DGGG), German Cancer Society (DKG): Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
  35. DeVita VT, Rosenberg SA (2012): Two hundred years of cancer research. N Engl J Med 366: 2207-2214 Google Scholar
  36. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M (2014): Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106: djt337Google Scholar
  37. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P (2017a): Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomized, phase 3 trial. Lancet Oncol 18: 1327-1337 Google Scholar
  38. Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P (2017b): Elotuzumab plus lenalidomide / dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyzes on progression-free survival and tumor growth. Br J Haematol 178: 896-905 Google Scholar
  39. Dobbelstein M, Moll U (2014): Targeting tumor-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13: 179-196Google Scholar
  40. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010): Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705 Google Scholar
  41. Early Breast Cancer Trialists ’Collaborative Group (EBCTCG) (2005): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717 Google Scholar
  42. Eichhorst B, Hallek M (2016): New therapy concepts for chronic lymphocytic leukemia. Oncologist 22: 283-294Google Scholar
  43. Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenkov Y, Robertson JF (2015): Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. J Clin Oncol 33: 3781-3787 Google Scholar
  44. Ernst E, Schmidt K, Steuer-Vogt MK (2003): Mistletoe for cancer? A systematic review of randomized clinical trials. Int J Cancer 107: 262-267 Google Scholar
  45. European Medicines Agency (2016): CHMP confirms recommendations for use of Zydelig. Patients should be monitored for infection and given antibiotics during and after treatment. 22 July 2016 EMA / 488322/2016. Internet: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002573.jsp&mid=WC0b01ac058001d126
  46. Evans JB, Syed BA (2014): From the analyst ‹s couch: Nextgeneration antibodies. Nat Rev Drug Discov 13: 413-414 Google Scholar
  47. Falchi L, Bose P, Newberry KJ, Verstovsek S (2017): Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol 176: 352-364 Google Scholar
  48. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group (2009): Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 10: 223-232 Google Scholar
  49. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016): Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375: 1925-1936Google Scholar
  50. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators (2017): Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 377: 352-360 Google Scholar
  51. Foà R (2014): Changes in the treatment landscape for chronic lymphoid leukemia. N Engl J Med 371: 273-274 Google Scholar
  52. Food and Drug Administration (2011): FDA Commissioner removes breast cancer indication from avastin label. Internet: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm
  53. Fruman DA, Rommel C (2014): PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13: 140-156 Google Scholar
  54. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S. , Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM (2014): Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370: 997-1007 Google Scholar
  55. Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S (2016): Diagnosis and therapy of multiple myeloma. Dtsch Ärztebl 113: 470–476Google Scholar
  56. Gharwan H, Groninger H (2016): Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 13: 209-227 Google Scholar
  57. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR (2016): Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375: 209-219 Google Scholar
  58. Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA (2016): First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016 May 25; (5): CD010383Google Scholar
  59. Gregory RK, Smith IE (2000): Vinorelbine - a clinical review. Br J Cancer 82: 1907-1913 Google Scholar
  60. Grgic T, Mis L, Hammond JM (2011): Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 45: 78-83 Google Scholar
  61. Hanahan D (2014): Rethinking the war on cancer. Lancet 383: 558-563 Google Scholar
  62. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010): The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9: 325-338Google Scholar
  63. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005): Hydroxyurea compared with anagrelide in highrisk essential thrombocythemia. N Engl J Med 353: 33-45 Google Scholar
  64. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012): JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798 Google Scholar
  65. Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigenler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017): Combined immune checkpoint blockade (anti-PD -1 / anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 57: 36-49Google Scholar
  66. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012): Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomized controlled trial. Lancet 380: 358-365 Google Scholar
  67. Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC , Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J (2017): Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31: 2398-2406Google Scholar
  68. Ho GY, Woodward N, Coward JI (2016): Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102: 37-46 Google Scholar
  69. Skyscraper A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O Brien SG, Druker BJ; IRIS Investigators (2017): Longterm outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376: 917-927 Google Scholar
  70. Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT (2008): Mitomycin C in the treatment of gastrointestinal tumors: recent data and perspectives. Oncology 31: 271-281Google Scholar
  71. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002): Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403 Google Scholar
  72. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004): Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605-1613 Google Scholar
  73. Hughes TP, Ross DM (2016): Moving treatment-free remission into mainstream clinical practice in CML. Blood 128: 17-23 Google Scholar
  74. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 Google Scholar
  75. IQVIA Institute for Human Data Science (2018): Global oncology trends 2018. Innovation, expansion and disruption. Parsippany: IQVIAGoogle Scholar
  76. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists ‹Group (2010): Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer program at a median follow-up of 9.7 years. BJU Int 105: 1074-1081 Google Scholar
  77. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O ‹Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators (2017): Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377: 338-351 Google Scholar
  78. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014): Ovarian cancer. Lancet 384: 1376-1388 Google Scholar
  79. Joppi R, Gerardi C, Bertele V, Garattini S (2016): Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ 353: i2978. doi: 10.1136 / bmj.i2978
  80. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016): Bladder cancer. Lancet 388: 2796-2810 Google Scholar
  81. Kamisawa T, Wood LD, Itoi T, Takaori K (2016): Pancreatic cancer. Lancet 388: 73-85 Google Scholar
  82. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017): Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376: 836-847 Google Scholar
  83. Khasraw M, Bell R, Dang C (2012): Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21: 142-149 Google Scholar
  84. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S (2015): Immunotherapy of tumors. Activated T cells as a new treatment principle. Dtsch Arztebl 112: 809–815Google Scholar
  85. Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ (2014): Non-steroidal antiandrogen monotherapy compared with luteinizing hormonereleasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. 2014 Jun 30; (6): CD009266Google Scholar
  86. Kundranda MN, Niu J (2015): Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 9: 3767-3777Google Scholar
  87. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010): Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703 Google Scholar
  88. Lao J, Madani J, Puértolas T, Alvarez M, Hernández A, Pazo-Cid R, Artal A, Antón Torres A (2013): Liposomal doxorubicin in the treatment of breast cancer patients: a review. Drug Deliv 2013: 456409Google Scholar
  89. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J , Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O ‹Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ , Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016): Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30: 1005-1017Google Scholar
  90. Lecavalier-Barsoum M, Quon H, Abdulkarim B (2014): Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. 2014 May 15; 5: CD007104Google Scholar
  91. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U (2012): Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Eng J Med 366: 1382-1392Google Scholar
  92. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014): Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol 15: 852-861